Targeted NPM1c derived new antigen TCR and application thereof

CN120665184APending Publication Date: 2025-09-19RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202510834309.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-07-15
Filing Date
2025-06-20
Publication Date
2025-09-19

Smart Images

  • Figure CN120665184A_ABST
    Figure CN120665184A_ABST
Patent Text Reader

Abstract

The invention provides a TCR targeting an NPM1c derived neoantigen, a nucleic acid molecule containing a nucleotide sequence encoding the TCR or a complementary sequence thereof, a carrier containing the nucleic acid molecule, a cell transducing the nucleic acid molecule or the carrier, and a pharmaceutical composition containing the TCR, the nucleic acid molecule, the carrier or the cell as an active component. The invention also discloses application of the TCR, the nucleic acid molecule, the carrier, the cell and the pharmaceutical composition in detection, prevention and / or treatment of NPM1c gene mutation derived neoantigen related cancers.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Tumor neoantigen immune repertoire data visualization analysis method and system

    CN115295084A